The challenges for establishing an early diagnosis of Alzheimer's disease (AD) have created a need for biomarkers that reflect the core pathology of the disease. The cerebrospinal fluid (CSF) levels of total Tau (T-tau), phosphorylated Tau (P-Tau) and beta-amyloid peptide (Ab 42 ) reflect, respectively, neurofibrillary tangle and amyloid pathologies and are considered as surrogate markers of AD pathophysiology. The combination of low Ab 42 and high levels of T-tau and P-Tau can accurately identify patients with AD at early stages, even before the development of dementia. The combined analysis of the CSF biomarkers is also helpful for the differential diagnosis between AD and other degenerative dementias. The development of these CSF biomarkers has evolved to a novel diagnostic definition of the disease. The identification of a specific clinical phenotype combined with the in vivo evidence of pathophysiological markers offers the possibility to make a diagnosis of AD before the dementia stage with high specificity.
BIOLOGICAL MARKERS OF ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common form of dementia, accounting for approximately 50-60% of all cases 1 . The most prominent feature of AD is the decline in cognitive function, with an early impairment of episodic memory 2 . The incidence of AD increases with age and, due to the increasing aging of populations and life expectancy, the prevalence of AD continues to rise worldwide. In this scenario, AD represents a major public health concern, with important social and economic outcomes 3 . There is still no curative treatment for AD, but many ongoing trials are actually evaluating new therapeutic strategies on different molecular targets. Among several factors, the efficacy of these disease-modifying treatments will depend of early and accurate diagnosis 4 . These treatments should be more efficient if they are administered at early stages of the disease and in well-defined groups of patients, which requires accurate tools for the early diagnosis.
The challenges for establishing an early and accurate diagnosis have created a need for biomarkers, which may be defined as "an objective measure of a biological or pathogenic process that can be used to evaluate disease risk or prognosis, to guide clinical diagnosis or to monitor therapeutic interventions" 5 . These biomarkers for AD include both neuroimaging and biological parameters. In this review, we will only focus on cerebrospinal fluid (CSF) biomarkers and present data demonstrating their added-value when they are applied to the clinical diagnosis and evaluation of AD.
CSF BIOMARKERS AS EVIDENCE OF THE PATHOLOGICAL PROCESS
Ideally, a biological marker of AD should detect with high accuracy a fundamental feature of AD's pathology early in the course of the disease 6 . The core pathological hallmarks of the AD are the extracellular deposits of Ab peptide and the intracellular accumulation of abnormally hyperphosphorylated tau protein. As the CSF is in direct contact with the extracellular space of the brain and also considering that the CSF usually reflects pathological changes in the brain, the CSF is an optimal source of pathophysiological markers 5, 7 . Currently, the main biological biomarkers employed in AD diagnosis are total Tau (Tau), the isoforms of phosphorylated Tau (P-Tau 181 and P-Tau 231 ) and b-amyloid peptide (Ab 42 ).
Some studies investigated the correlations between antemortem CSF biomarker levels (Tau, P-Tau and Ab proteins) and AD-type neuropathologic changes in the brain 6, [8] [9] [10] . Data from these clinico-pathological studies showed that CSF levels of total Tau reflect the intensity of neuronal degeneration, while P-tau reflects tangle pathology. It has also been demonstrated that antemortem Ab 42 is inversely correlated with Ab plaque counts at post-mortem examination 9 . Moreover, there is an inverse correlation between CSF Ab 42 levels and the overall retention of the amyloid tracer Pittsburgh compound B (PiB) with positron-emission tomography investigation 11, 12 . These findings have been recently confirmed by a study that analyzed relationships between AD pathology in cortical brain biopsy and AD biomarkers in a series of 182 patients 13 , showing that the amount of amyloid plaques and hyperphosphorylated Tau in cortical brain biopsies are associated with low CSF Ab 42 and high CSF levels of Tau markers, respectively. It was also demonstrated a concordance of 94% between CSF markers and neuropathological diagnosis in a sample of patients from a memory clinic 14 . Taken together, data from clinico-pathological studies support the view of CSF biomarkers as surrogate markers of the pathophysiological process of AD 5 .
SENSITIVITY AND SPECIFICITY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEASE
During the last two decades, a multitude of studies has consistently demonstrated that AD patients exhibit a decrease in CSF Ab 42 and an increase in CSF Tau and Ptau when compared with healthy controls 5, 7, 15 . Data provided by these studies confirm that each of these biomarkers differentiates AD patients from age-matched controls with 80-90% sensitivity and specificity 5, 7 . The CSF Ab 42 levels are around 50% lower in AD patients than in aged-matched normal subjects 16 . The aggregation of Ab protein in amyloid plaques and the consequent reduction of its availability in the CSF are the suggested mechanisms to explain the reduction of CSF Ab 42 levels in AD patients 5 . It should be noted, however, that a reduction of CSF Ab 42 levels may also occur in other diseases, such as Lewy body dementia, vascular dementia and cerebral amyloid angiopathy 14, 17, 18 . Hence, although a decreased level of Ab 42 is characteristic of AD, it is not sufficient for an etiologic diagnosis of AD.
Tau is considered to be a non-specific marker of neuronal lesion associated to a variety of biological processes 7 . In AD patients, total Tau CSF levels are about three times higher than in age-matched controls 16 . Isolated high total Tau protein levels can also be detected in other acute neurodegenerative diseases and brain lesions, such as head trauma, stroke, and in Creutzfeldt-Jakob disease 5, 7, 14 . On the contrary, P-Tau protein (subtypes P-Tau 181 and P-Tau 231 ) is the most specific biomarker of AD, being normal in non-AD diseases, including those in which Tau protein levels may be increased, such as Creutzfeldt-Jakob disease and stroke 14 . It is well established that the best accuracy in the differential diagnosis between AD patients and controls is obtained with the combined analysis of two or more of the three main AD CSF markers (total Tau, P-Tau and Ab 42 ). Association of Ab 42 with Tau or P-Tau improves both sensitivity and specificity of AD diagnosis when compared to any of the markers alone. The value of the combined approach of CSF biomarkers was demonstrated by a study with neuropathological confirmation of the diagnosis, which showed that the ratio P-Tau/Ab 42 has a sensitivity of 91.6% and a specificity of 85.7% for AD diagnosis 6 . In order to consider the combined analysis of biomarkers, some ratios have been proposed, as the Innotest Amyloid-Tau Index (IATI), defined by the ratio Ab 42 /(240+1.18 x Tau) 19, 20 , the AD-CSF-Index 21 , and the ratios Tau/Ab 42 and P-Tau/Ab 42 . An IATI score inferior to 1 has been proposed as suggestive of AD but, given the high prevalence (31%) of control subjects without cognitive impairment with this profile 22 , this cut-off does not seem to be specific.
CSF BIOMARKERS IN THE PRODROMAL STAGE (PRE-DEMENTIA) OF ALZHEIMER'S DISEASE
The pathophysiological process of AD starts decades before the clinical onset of the disease, with a gradual loss of synapses, axons and neurons that progress before the appearance of the first cognitive symptoms, most often episodic memory impairment 23 . The dementia that characterizes the severe stage of the disease is thus preceded by a clinical phase in which the patients present memory impairment in an intermediate degree between age-matched normal controls and patients fulfilling clinical criteria for AD. This symptomatic predementia phase is characterized by a preserved autonomy and may be referred as mild cognitive impairment (MCI) 24 . During the last decade, large cohort studies have consistently shown that an AD biomarker profile distinguishes with high accuracy (up to 95% sensitivity) MCI patients who will progress to AD from healthy controls and from MCI patients who will remain cognitively stable during the follow-up. These longitudinal studies showed that "MCI-converters" have a biological profile characterized by low Ab 42 associated with high levels of CSF total Tau and P-Tau, while "MCI-stable" patients have a normal biomarker profile 22, [25] [26] [27] . Taken together, these data support the validity of CSF markers for identifying incipient AD among patients with mild cognitive impairment 5 . These patients with objective memory deficit, preserved autonomy and an AD signature at CSF analysis may be referred as "prodromal AD" 28 . Besides predementia stages of AD, abnormalities on CSF measures can be eventually observed in subjects without cognitive complaints 22, 23 , which is in line with the current knowledge on AD pathophysiology. According to it, the first clinical symptoms of AD are preceded by a long pathophysiological process. It should be noted, however, that the accumulated data from clinical studies do not allow the assumption of progression from normal cognition to AD in asymptomatic subjects with any specific biomarker of AD 29 . Therefore, at this time, the concept of "preclinical AD" is restricted only for research, and cannot be translated into a recommendation for the clinical practice 29 .
THE PROGNOSTIC VALUE OF CSF BIOMARKERS
A series of studies investigated whether CSF biomarkers are correlated to clinical and imaging markers of AD severity. Data from a longitudinal study suggested that low Ab 42 , elevated Tau level and high Tau/Ab 42 are predictive of a faster cognitive decline during a follow-up of one year 30 . Patients with extreme alterations in CSF biomarkers (Ab 42 reduction and increased total Tau and P-Tau) appear to progress unfavorably, with a more severe cognitive decline, poor response to anticholinesterase treatment and higher mortality 31 . CSF markers may also be useful to identify subgroups of AD patients with distinctive clinical and neuropsychological profiles which may be associated with more severe cognitive impairment 32, 33 . Neuroimaging studies with structural brain MRI have also reported a significant positive correlation between the increased levels of Tau markers (total Tau and P-Tau) and the severity of hippocampal atrophy [34] [35] [36] [37] [38] [39] . High levels of CSF total Tau and P-Tau seem also to be related to a faster progression of hippocampal atrophy [36] [37] [38] . These data suggest that CSF markers may be predictive of the clinical severity in specific groups of AD patients. These findings, however, need further validation.
CSF BIOMARKERS FOR THE DIFFERENTIAL DIAGNOSIS BETWEEN ALZHEIMER'S DISEASE AND OTHER DEMENTIAS
The analysis of CSF biomarkers has been increasingly employed in the differential diagnosis between AD and other dementias 14, [40] [41] [42] [43] [44] . Data from different centers consistently confirmed that the combined analysis of the CSF biomarkers provides the best accuracy in the differential diagnosis between AD and other degenerative dementias 14, 40, 42 . Particularly, the P-Tau/Ab 42 was the best biomarker for differentiating AD from the behavioral variant of frontotemporal lobar degeneration and from semantic dementia, with a sensitivity of 91.7% and 98.3%, respectively, and a specificity of 92.6% and 84.2%, respectively 42 . These results in terms of performance for the differential diagnosis between AD and frontotemporal lobar degeneration are in agreement with previous findings showing a specificity of 96.6% in a series of patients with diagnostic confirmation either by genetics or by post-mortem examination 40 . CSF biomarkers are also useful for identifying patients with focal atypical presentations of AD. In contrast to the typical amnestic profile "of the hippocampal type", atypical focal forms of AD include non-amnestic focal cortical syndromes 45 , such as posterior cortical atrophy (PCA), logopenic aphasia and the frontal variant of AD 28, [46] [47] [48] [49] [50] which exhibit characteristic histological lesions of AD-type pathology at post-mortem examination. For instance, AD-type pathology is the retained diagnosis in more than 80% of PCA cases at post-mortem examination 46, 51 and in almost 60% of patients with primary progressive aphasia (PPA) 52, 53 . In these groups of patients, data on biomarker assays are consistent with the pathological studies, as it was observed that 60% of PCA patients (9/15) and 61.5% (16/26) of aphasic subjects had an AD biological profile, with both altered Tau/Ab 42 and P-Tau/Ab 42 ratios 42 . Moreover, a concordance between CSF markers and amyloid imaging with PiB was reported in a group of patients with PCA 54 . Also interestingly, in a series of 34 patients with PPA who underwent both brain perfusion SPECT and lumbar puncture for CSF biomarkers, two distinct brain perfusion profiles were observed: PPA patients with an AD CSF profile presented a perfusion pattern similar to that observed in logopenic aphasia, and those PPA patients without an AD CSF biomarker profile showed a brain perfusion pattern similar to that has been described in semantic dementia 55 . Indeed, other studies demonstrated that logopenic aphasia is associated with significant PiB uptake, while semantic dementia and non-fluent aphasia do not exhibit amyloidosis on molecular imaging 56, 57 , in agreement with the classification of logopenic aphasia as a focal variant of AD, and non-fluent APP and semantic dementia as language variants of frontotemporal lobar degeneration 58 . AD pathology may also be observed in patients with behavioral presentation mimicking behavioral variant of frontotemporal lobar degeneration, the so-called frontal variant of AD 46, 48, 59 . Taken together, these data support using CSF biomarkers for identifying AD pathology in patients with atypical presentations. By identifying an underlying AD pathology in these patients, CSF biomarkers are useful as their positivity may reorient the diagnosis and, hence, the therapeutics 14 .
FINAL REMARKS
The development of CSF biomarkers of AD led to a new diagnostic definition of the disease. The use of biological markers in association with the clinical approach opens the possibility to establish a diagnosis of AD before the dementia stage, differently from the previous National Institute of Neurological and Communication Disorders and Stroke -Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria 60 . The core clinical criteria remain the main landmark of the diagnosis of AD in the clinical practice, but biological evidence provided by CSF increases the specificity of the diagnosis. By using CSF markers, it is now possible to establish an etiological diagnosis in vivo, which enables identifying patients at predementia stages of the disease and patients with atypical focal presentations of AD 52 . This is crucial in the perspective of new disease-modifying drugs that will tackle specific pathophysiological targets.
